Rothschild & Co Redburn initiated coverage of Insmed (INSM) with a Buy rating and $263 price target The firm believes the company is well positioned in “large” therapy areas with limited competition. The company’s of Brinsupri, a first-in-class therapy for bronchiectasis, should see strong uptake given the lack of competitors, the analyst tells investors in a research note. Rothschild thinks Brinsupri has peak sales of $12B, above the consensus median of $10B.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $256 from $196 at Mizuho
- Insmed price target raised to $231 from $223 at TD Cowen
- Insmed’s Brinsupri Approval and Strategic Market Expansion Justify Buy Rating
- Insmed’s BRINSUPRI Approved by European Commission
- Insmed’s Brinsupri approved in EU for non-cystic fibrosis bronchiectasis